{'fraction_non_alphanumeric': 0.04957264957264957, 'fraction_numerical': 0.022222222222222223, 'mean_word_length': 5.7298850574712645, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 1, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond.

3 J Clin Psychiatry 2007;68 (suppl 1) From the Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio. This article is derived from the planning teleconference “Evaluating the Evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and Beyond,” which was held on May 10, 2006, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Health and Wellness Education Partners (HWeP) pursuant to an educational grant from Pfizer Inc and additional financial support from HWP Publishing. Dr. Nasrallah is a consultant for, has received honoraria from, and is a member of the speakers/advisory boards for Abbott, AstraZeneca, Janssen, Pfizer, and Shire, and has received grant/research support from AstraZeneca, Janssen, and Pfizer. Corresponding author and reprints: Henry A. Nasrallah, M.D., Department of Psychiatry, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0559 (e-mail: henry.nasrallah@uc.edu). Introduction